Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: A pharmacodynamic interaction?

Epilepsy and Behavior

Volumn 20, Issue 1, 2011, Pages 20-23

  Novy, Jan ^a   Patsalos, Philip N ^a   Sander, Josemir W ^a,b   Sisodiya, Sanjay M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

Drug load; Interaction; Lacosamide; Pharmacodynamics; Sodium voltage gated channel

Indexed keywords

ACETAZOLAMIDE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; LICARBAZEPINE; MESUXIMIDE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; RUFINAMIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; VOLTAGE GATED SODIUM CHANNEL; ZONISAMIDE;

ADULT; ALERTNESS; ANTICONVULSANT THERAPY; ARTICLE; ATAXIA; BLURRED VISION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPLEX PARTIAL SEIZURE; DIPLOPIA; DIZZINESS; DROP ATTACK; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; FOCAL EPILEPSY; FRONTAL LOBE EPILEPSY; GRAND MAL SEIZURE; HUMAN; MALE; NEUROTOXICITY; RIGHT FRONTAL; SEIZURE; SIDE EFFECT; SIMPLE PARTIAL SEIZURE; SYMPTOMATIC EPILEPSY; TONIC CLONIC SEIZURE; UNSTEADINESS; VERTIGO;

ACETAMIDES; ADULT; AGED; ANTICONVULSANTS; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; SODIUM CHANNEL BLOCKERS;

EID: 78651251889     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2010.10.002     Document Type: Article

References (18)

1. Halasz P., Kalviainen R., Mazurkiewicz-Beldzinska M., et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009, 50:443-453.
2. Chung S., Sperling M.R., Biton V., et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010, 51:958-967.
3. Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd G.D. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007, 48:1308-1317.
4. Horstmann R., Bonn R., Cawello W., Doty P., Rudd D. Basic clinical pharmacologic investigations of the new antiepileptic drug SPM 927. Epilepsia 2002, 43(Suppl. 7):188.
5. Johannessen Landmark C., Patsalos P.N. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 2010, 10:119-140.
6. Cawello W., Nickel B., Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol 2010, 50:459-471.
7. Errington A.C., Stohr T., Heers C., Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008, 73:157-169.
8. Beyreuther B.K., Freitag J., Heers C., Krebsfanger N., Scharfenecker U., Stohr T. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007, 13:21-42.
9. Wang Y., Brittain J.M., Jarecki B.W., et al. In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein 2 (CRMP-2) identifies a pocket important in modulating sodium channel slow inactivation. J Biol Chem 2010, 285:25296-25307.
10. Wehner T., Bauer S., Hamer H.M., et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009, 16:423-425.
11. Greenaway C., Ratnaraj N., Sander J.W., Patsalos P.N. A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy. Ther Drug Monit 2010, 32:448-452.
12. Deckers C.L., Hekster Y.A., Keyser A., Meinardi H., Renier W.O. Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects. Epilepsia 1997, 38:570-575.
13. + channels. Mol Pharmacol 1998, 54:712-721.
14. Tate S.K., Depondt C., Sisodiya S.M., et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA 2005, 102:5507-5512.
15. Errington A.C., Coyne L., Stohr T., Selve N., Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006, 50:1016-1029.
16. Xiong W., Li R.A., Tian Y., Tomaselli G.F. Molecular motions of the outer ring of charge of the sodium channel. J Gen Physiol 2003, 122:323-332.
17. Cardenas C.A., Cardenas C.G., de Armendi A.J., Scroggs R.S. Carbamazepine interacts with a slow inactivation state of NaV1.8-like sodium channels. Neurosci Lett 2006, 408:129-134.
18. Patsalos P.N., Berry D.J., Bourgeois B.F., et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008, 49:1239-1276.